SCHEMBL2530685

SCHEMBL2530685

O=C1C(SCCO)=C(SCCO)C(=O)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 13/20 1.00
S100A4 P26447 8/20 1.00
CDC25A P30304 7/20 1.00
MAP2K7 O14733 5/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
APAF1 O14727 3/20 1.00
TDP2 O95551 3/20 1.00
CDC25C P30307 2/20 1.00
KDM4E B2RXH2 2/20 1.00
NPC1 O15118 2/20 1.00
LMNA P02545 2/20 1.00
PLA2G1B P04054 2/20 1.00
MAPT P10636 2/20 1.00
THRB P10828 2/20 1.00
MAPK1 P28482 2/20 1.00
RECQL P46063 2/20 1.00
RAB9A P51151 2/20 1.00
GALK1 P51570 2/20 1.00
BLM P54132 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17323863 0.91 CDC25B (0.83) CDC25BS100A4CDC25AMAP2K7MEN1
SCHEMBL16138413 0.89 CDC25B (0.80) CDC25BS100A4CDC25AMAP2K7MEN1
SCHEMBL2599202 0.89 CDC25B (1.00) CDC25BS100A4CDC25AMAP2K7MEN1
SCHEMBL15630311 0.87 CDC25A (0.77) CDC25BS100A4CDC25AMAP2K7MEN1
SCHEMBL15679343 0.83 CDC25B (0.70) CDC25BS100A4CDC25AMAP2K7MEN1
SCHEMBL23567913 0.81 CDC25B (0.74) CDC25BS100A4CDC25AMAP2K7MEN1
SCHEMBL20398309 0.78 CDC25B (0.64) CDC25BS100A4CDC25AMAP2K7MEN1
SCHEMBL2599403 0.76 S100A4 (1.00) CDC25BS100A4CDC25AMAP2K7MEN1
SCHEMBL4629512 0.76 S100A4 (0.76) CDC25BS100A4CDC25AMAP2K7MEN1
SCHEMBL1197875 0.76 NPC1 (0.61) CDC25BS100A4CDC25AMAP2K7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4057813-A1 COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS New Life Crop Sciences LLC (US) 2022-09-21 EP claimed
CN-114980736-A Compositions and methods for treating citrus greening disease 新生命作物科学有限责任公司 2022-08-30 CN claimed
US-20210144998-A1 COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS NEW LIFE CROP SCIENCES LLC 2021-05-20 US claimed
US-10543282-B2 Targeted peptide conjugates MARKER GENE TECHNOLOGIES, INC (US) 2020-01-28 US claimed
US-20180207287-A1 TARGETED PEPTIDE CONJUGATES MARKER GENE TECHNOLOGIES, INC. 2018-07-26 US claimed
US-9018176-B2 Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-28 US claimed
US-20130090355-A1 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2013-04-11 US claimed
WO-2011146101-A1 CHEMICAL AGENTS FOR THE PREVENTION OR INHIBITION OF TUMOR METASTASIS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2011-11-24 WO claimed
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY ZOUNEK ALEX (DE) 2025-12-18 US disclosed
US-20250027041-A1 COMPOSITION FOR INDUCING TRANSDIFFERENTIATION AND STEM CELLS TREATED THEREWITH YJ Cerapeutics Inc. (KR) 2025-01-23 US disclosed
WO-2024242637-A1 A NOVEL SELF-AMPLIFYING RNA NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2024-11-28 WO disclosed
EP-4455273-A1 COMPOSITION FOR INDUCING TRANSDIFFERENTIATION AND STEM CELLS TREATED THEREWITH YJ Cerapeutics Inc. (KR) 2024-10-30 EP disclosed
CN-118284688-A Composition for direct transdifferentiation induction and stem cell treated with the same 外治世拉普提斯株式会社 2024-07-02 CN disclosed
WO-2023090971-A1 COMPOSITION FOR INDUCING TRANSDIFFERENTIATION AND STEM CELLS TREATED THEREWITH 주식회사 와이제이세라퓨틱스 2023-05-25 WO disclosed
CN-101415420-A Combination of therapeutic agents for the treatment of cancer NOVARTIS AG (CH) 2009-04-22 CN disclosed
US-20090012107-A1 Antiviral Compounds and Methods of Using Thereof U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2009-01-08 US disclosed
US-20070258913-A1 Composition for Inhibiting or Preventing the Formation of a Biofilm OYSTERSHELL NV (BE) 2007-11-08 US disclosed
EP-1796656-A2 COMPOSITION FOR INHIBITING OR PREVENTING THE FORMATION OF A BIOFILM Oystershell NV (BE) 2007-06-20 EP disclosed
US-20060223092-A1 Assays, methods and kits for detecting small nuclear ribonucleoprotein particle assembly and survival of motor neurons activity THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2006-10-05 US disclosed
WO-2006029893-A2 COMPOSITION FOR INHIBITING OR PREVENTING THE FORMATION OF A BIOFILM OYSTERSHELL NV (BE) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY KIT, CTSL, PAICS CDC25B 69/4885S100A4 3477/4885CDC25A 91/4885
US-20090012107-A1 Antiviral Compounds and Methods of Using Thereof ZC3HAV1, MAVS, ZC3HAV1L CDC25B 3675/4885S100A4 1628/4885CDC25A 3086/4885
US-20250027041-A1 COMPOSITION FOR INDUCING TRANSDIFFERENTIATION AND STEM CELLS TREATED THEREWITH CTBP2, TARDBP, NES CDC25B 3641/4885S100A4 632/4885CDC25A 3433/4885
US-20070258913-A1 Composition for Inhibiting or Preventing the Formation of a Biofilm NQO2, NFKBIA, CROCC CDC25B 2143/4885S100A4 3710/4885CDC25A 1650/4885
US-20130090355-A1 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS S100A4, S100A6, S100A10 CDC25B 211/4885S100A4 1/4885CDC25A 248/4885
US-20180207287-A1 TARGETED PEPTIDE CONJUGATES VCP, NLN, GOLT1B CDC25B 3840/4885S100A4 4627/4885CDC25A 3958/4885
US-10543282-B2 Targeted peptide conjugates VCP, NLN, GOLT1B CDC25B 3840/4885S100A4 4627/4885CDC25A 3958/4885
US-20210144998-A1 COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS PNPO, G6PD, AGXT CDC25B 1481/4885S100A4 2971/4885CDC25A 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.